Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2009
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2576232C Neuroprotective properties of dextrorotatory morphinans
10/27/2009CA2567935C Aminopyridine derivatives as selective dopamine d3 agonists
10/27/2009CA2520813C Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
10/27/2009CA2516400C Intranasal formulation of rotigotine
10/27/2009CA2511664C 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders
10/27/2009CA2494234C Methods and dosage forms for controlled delivery of paliperidone
10/27/2009CA2493359C Novel polymorph of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-.alpha.]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2465534C Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2435426C Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/27/2009CA2422210C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2415050C Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo[2,1-b][1,3]benzothiazepines
10/27/2009CA2414584C 7-hydroxyepiandrosterone having neuroprotective activity
10/27/2009CA2406044C Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2379021C New phenylpiperazines
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2349529C Pge synthase and methods and means for modulating its activity
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/27/2009CA2243474C Quinolin-2-(1h)-ones
10/22/2009WO2009129548A1 Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
10/22/2009WO2009129546A1 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
10/22/2009WO2009129545A1 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
10/22/2009WO2009129532A1 Compounds for lysosomal modulation and methods of use
10/22/2009WO2009129476A2 An antibody bound synthetic vesicle containing active agent molecules
10/22/2009WO2009129428A2 Methods for treating post-operative effects such as spasticity and shivering with clonidine
10/22/2009WO2009129401A1 Kinase inhibitors
10/22/2009WO2009129361A2 Macrocyclic compounds and methods of making and using thereof
10/22/2009WO2009129259A2 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/22/2009WO2009129181A1 Propanediol-dicarbamate derivatives
10/22/2009WO2009129163A2 Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
10/22/2009WO2009128772A1 Stable amyloid beta monomers and oligomers
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128537A1 Heterocyclic compound
10/22/2009WO2009128446A1 Ameliorating agent for neurogenic pain
10/22/2009WO2009128383A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
10/22/2009WO2009128262A1 Quinolone derivative and use thereof
10/22/2009WO2009128058A1 Psycho-pharmaceuticals
10/22/2009WO2009128057A2 Psycho-pharmaceuticals
10/22/2009WO2009128050A2 Pharmaceutical composition and its use
10/22/2009WO2009127949A1 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127948A1 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127946A1 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127944A1 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127943A1 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127737A1 Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
10/22/2009WO2009127679A1 Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
10/22/2009WO2009127678A1 Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
10/22/2009WO2009127642A2 Use of lrrk2 inhibitors for neurodegenerative diseases
10/22/2009WO2009127566A1 Bifidobacterium longum and hippocampal bdnf expression
10/22/2009WO2009127320A1 Tertiary amine derivatives as phosphodiesterase-4 inhibitors
10/22/2009WO2009127218A1 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
10/22/2009WO2009127210A1 Vasodilating agents for the treatment of sleep attacks
10/22/2009WO2009127130A1 Achyranthes bidentata polypeptide and production methods and uses thereof
10/22/2009WO2009127048A1 Method of treating demyelinating diesase
10/22/2009WO2009102172A3 Pharmaceutical formulation containing choline alfoscerate
10/22/2009WO2009094577A3 Mesophasic forms of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
10/22/2009WO2009092129A8 Delayed release pharmaceutical composition of duloxetine
10/22/2009WO2009091605A3 Taste titration therapies
10/22/2009WO2009073192A3 Systems and methods for delivery of materials
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009US20090264855 Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil
10/22/2009US20090264656 Method for manufacture of sertindole
10/22/2009US20090264531 Sulindac formulations in a biodegradable material
10/22/2009US20090264530 Combined nsaid and acetaminophen formulation and method
10/22/2009US20090264524 Agent for recovery from cerebral fatigue
10/22/2009US20090264521 Percutaneous absorption preparation
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264501 Methods and Compositions to Inhibit P2x7 Receptor Expression
10/22/2009US20090264491 Methods and compositions for treating post-operative pain comprising clonidine
10/22/2009US20090264490 Clonidine formulations in a biodegradable polymer carrier
10/22/2009US20090264489 Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
10/22/2009US20090264480 Trpa1 antagonists
10/22/2009US20090264477 Beta adrenergic receptor agonists for treatment of pain and/or inflammation
10/22/2009US20090264458 5-ht7 receptor antagonists
10/22/2009US20090264457 Combination of at least two 5HT6-Ligands
10/22/2009US20090264456 Compostions and methods for preventing and/or treating disorders asociated with cephalic pain
10/22/2009US20090264454 Combined hydrocodone and analgesic formulation and method
10/22/2009US20090264451 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
10/22/2009US20090264437 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264422 Method of treating disease states using substituted pyrazole compounds
10/22/2009US20090264419 CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
10/22/2009US20090264418 such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-pyrrolidin-1-yl-methanone, useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors
10/22/2009US20090264408 Extended release dosage forms of quetiapine
10/22/2009US20090264404 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
10/22/2009US20090264400 Substituted Sulfonamide Compounds
10/22/2009US20090264399 Heterocyclic janus kinase 3 inhibitors
10/22/2009US20090264374 Utilization of anti-neuropathic pain effect of d-allose and d-psicose
10/22/2009US20090264369 Methods for reducing cd36 expression
10/22/2009US20090264355 Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject
1 ... 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 ... 1833